FMS Fresenius Medical Care AG

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of June 2018

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F    x                                                                                                                      Form 40-F    o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes    o                                                                                                                                                             No    x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

On June 29, 2018, Fresenius Medical Care AG & Co. KGaA (the “Company”) filed a prospectus for approval with the Commission de Surveillance du Secteur Financier (“CSSF”) for a €10 billion debt issuance program (“Program”). The notes issued under the Program will be guaranteed by Fresenius Medical Care Holdings, Inc. (“FMCH”) and the Company has filed the audited consolidated financial statements of FMCH as of and for the years ended December 31, 2017 and 2016 with the CSSF. These audited consolidated financial statements are available on the website of the Luxembourg Stock Exchange (“LSE”). The Company has also posted the audited consolidated FMCH financial statements on the Company’s website.

The FMCH financial statements are being filed solely to comply with the requirements of Form 6-K and the Securities and Exchange Commission Rule 13a-16. Any notes under the Program may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. Further, any notes under the Program will not be offered for sale in the US or to “US persons” (as defined in Regulation S under the US Securities Act of 1933, as amended).

2